Accelerating the End of Breast Cancer Act of 2011 - Directs the President to establish the Commission to Accelerate the End of Breast Cancer to help end breast cancer by January 1, 2020.
Directs the Commission to: (1) identify opportunities and ideas within government and the private sector that are key components in achieving the end of breast cancer and which have been overlooked, yet are ripe for collaboration and investment; (2) recommend projects to leverage such opportunities and ideas in the areas of the primary prevention of breast cancer and the causes and prevention of breast cancer metastasis; and (3) ensure that its activities are coordinated with, and do not duplicate the efforts of, programs and laboratories of other government agencies.
Directs the President to enter into an agreement with the Institute of Medicine for an evaluation of the Commission's progress.
Terminates the Commission on June 1, 2020.
[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3067 Introduced in House (IH)]
112th CONGRESS
1st Session
H. R. 3067
To provide for the establishment of a Commission to Accelerate the End
of Breast Cancer.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 26, 2011
Ms. Bass of California (for herself, Mr. Bass of New Hampshire, Ms.
Hanabusa, Mr. Scalise, Ms. Moore, Mrs. Capito, and Ms. DeLauro)
introduced the following bill; which was referred to the Committee on
Energy and Commerce
_______________________________________________________________________
A BILL
To provide for the establishment of a Commission to Accelerate the End
of Breast Cancer.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Accelerating the End of Breast
Cancer Act of 2011''.
SEC. 2. TABLE OF CONTENTS.
The table of contents of this Act is as follows:
Sec. 1. Short title.
Sec. 2. Table of contents.
Sec. 3. Findings.
Sec. 4. Establishment.
Sec. 5. Mission; duties.
Sec. 6. Membership.
Sec. 7. Chairperson and commissioners.
Sec. 8. Coordination and nonduplication.
Sec. 9. Evaluation of the commission.
Sec. 10. Termination.
SEC. 3. FINDINGS.
The Congress finds the following:
(1) In the United States, the chance of a woman developing
breast cancer during her lifetime has increased from 1 in 11 in
1975 to 1 in 8 today.
(2) Worldwide, breast cancer is the most frequently
diagnosed cancer in women with 1.3 million cases each year and
the leading cause of cancer death with more than 500,000 women
dying from the disease in 2010.
(3) More than 90 percent of deaths from breast cancer are
caused by metastasis, when breast cancer has spread to other
organs or bone.
(4) The National Cancer Institute estimated that breast
cancer care in the United States cost $16.5 billion in 2009 and
cost the Nation $12.1 billion in lost productivity.
(5) Very little has improved in terms of breast cancer
incidence, morbidity, and mortality rates over the past 40
years.
SEC. 4. ESTABLISHMENT.
The President shall establish a commission to be known as the
Commission to Accelerate the End of Breast Cancer (in this Act referred
to as the ``the Commission'').
SEC. 5. MISSION; DUTIES.
(a) Mission.--The mission of the Commission shall be to help end
breast cancer by January 1, 2020.
(b) Duties.--The Commission shall--
(1) identify opportunities and ideas within government and
the private sector that are key components in achieving the end
of breast cancer and which have been overlooked, yet are ripe
for collaboration and investment, and
(2) recommend projects to leverage such opportunities and
ideas in the areas of--
(A) the primary prevention of breast cancer; and
(B) the causes and prevention of breast cancer
metastasis.
(c) Means.--In carrying out the duties described in subsection (b),
the Commission shall--
(1) identify revolutionary opportunities and ideas in
fundamental and applied sciences and epidemiology with a focus
on ending breast cancer;
(2) identify timely opportunities and scientific
discoveries which can be turned into real world strategies to
prevent breast cancer and prevent breast cancer metastasis and
deaths;
(3) promote ideas that are intellectually compelling,
innovative, and imaginative;
(4) accelerate potential transformational scientific
advances--
(A) not being prioritized within the Federal
Government, but which can help to achieve the mission
described in subsection (a); and
(B) unlikely to be achieved by the private sector
due to technical and financial uncertainty;
(5) identify promising, underdeveloped areas of research
that would benefit from a cluster of government, industry, and
academia forming innovation communities to rapidly advance
knowledge into practice, while creating new opportunities for
job creation and advancement;
(6) identify opportunities for transdisciplinary cross-
cutting collaborations; and
(7) identify opportunities for seed grants to leverage
identified opportunities and ideas.
(d) Strategic Vision.--Not later than 6 months after the
appointment of the initial members of the Commission, the Commission
shall submit to the President and the relevant authorizing and
appropriations committees of the Congress a description of the
Commission's strategic vision for making progress in achieving the
mission described in subsection (a) by January 1, 2020.
(e) Annual Reports.--The Commission shall submit an annual report
to the President, the Congress, and the public describing the
Commission's activities under this section, including its progress in
achieving the mission described in subsection (a).
SEC. 6. MEMBERSHIP.
(a) Number; Appointment.--The Commission shall be composed of not
more than 10 members, of which--
(1) not more than 8 shall be appointed by the President;
(2) 1 shall be appointed by the Speaker of the House of
Representatives; and
(3) 1 shall be appointed by the majority leader of the
Senate.
(b) Composition.--
(1) In general.--Each member of the Commission shall be
appointed to represent one of the following 3 categories:
(A) Representatives of varied disciplines within
the biomedical research field.
(B) Representatives of varied disciplines outside
of the biomedical research field.
(C) Educated patient advocates, meaning individuals
who--
(i) represent a patient-led, patient-
centered organization with a patient
constituency;
(ii) have been personally affected by
breast cancer; and
(iii) are trained, knowledgeable, and
prepared to participate in the decisionmaking
process of science and medicine.
(2) Representation of membership categories.--Of the
members of the Commission--
(A) at least 1 but not more than 3 shall be
appointed to represent the category described in
paragraph (1)(A);
(B) at least 1 but not more than 3 shall be
appointed to represent the category described in
paragraph (1)(B); and
(C) at least 2 but not more than 4 shall be
appointed to represent the category described in
paragraph (1)(C).
(c) Initial Members.--The initial members of the Commission shall
be appointed not later than 60 days after the date of the enactment of
this Act.
(d) Terms.--
(1) In general.--Each member of the Commission shall be
appointed for a term of 3 years and may be reappointed.
(2) Vacancies.--Any member of the Commission appointed to
fill a vacancy occurring before the expiration of the term for
which the member's predecessor was appointed shall be appointed
only for the remainder of that term. A member may serve after
the expiration of that member's term until a successor has
taken office. A vacancy in the Commission shall be filled in
the manner in which the original appointment was made.
(e) Quorum.--Three members of the Commission shall constitute a
quorum.
SEC. 7. CHAIRPERSON AND COMMISSIONERS.
(a) Chairperson.--
(1) Designation.--Of the members of the Commission
appointed under section 6(a), the President shall at the time
of appointment, designate one to serve as Chairperson of the
Commission.
(2) Qualifications.--The Chairperson shall be an individual
who, by reason of professional background and experience, is
especially qualified to manage areas of study pertaining to
ending breast cancer by January 1, 2020.
(3) Responsibilities.--The responsibilities of the
Chairperson shall include--
(A) approving all new study projects and areas of
study of the Commission based on innovation, impact,
and scientific and technical merit;
(B) developing criteria (including milestones) for
assessing, and overseeing assessment of, the success of
the study projects and areas of study of the
Commission;
(C) identifying opportunities for seed grants and
other funding through awards, prizes, grants, and
contracts to achieve the mission described in section
5(a); and
(D) terminating study projects and areas of study
of the Commission that are not achieving the mission
described in section 5(a).
(b) Commissioners.--
(1) In general.--The Chairperson of the Commission may
appoint members of the Commission to oversee one or more areas
of study of the Commission.
(2) Responsibilities.--A member appointed under paragraph
(1) shall, with respect to one or more areas of study, be
responsible for--
(A) recommending novel proposals, projects, and
collaborations based on scientific and technical merit
to achieve the mission described in section 5(a) with a
focus on strategies for the primary prevention of
breast cancer, and methods to prevent breast cancer
metastasis;
(B) identifying ideas and opportunities to achieve
the mission described in section 5(a) that are
intellectually compelling, innovative, and imaginative,
including such ideas and opportunities not being
prioritized for breast cancer relevance within Federal
agencies or programs or the private sector;
(C) working with other relevant Federal agencies to
identify areas of concurrent interests in order to
maximize Federal investment and stimulate collaborative
projects;
(D) identifying opportunities for
transdisciplinary, cross-cutting collaborations; and
(E) monitoring the progress of study projects and
areas of study and recommending restructure or
termination.
SEC. 8. COORDINATION AND NONDUPLICATION.
To the maximum extent practicable, the Commission shall ensure that
the activities of the Commission are coordinated with, and do not
duplicate the efforts of, programs and laboratories of other government
agencies.
SEC. 9. EVALUATION OF THE COMMISSION.
(a) In General.--The President shall seek to enter into an
agreement with the Institute of Medicine of the National Academy of
Sciences under which the Institute, after the Commission has been in
operation for 3 years, completes an evaluation of how well the
Commission is making progress towards achieving the mission described
in section 5(a).
(b) Inclusions.--The evaluation under subsection (a) shall
include--
(1) a recommendation on whether the Commission should be
continued or terminated; and
(2) a description of lessons learned from operation of the
Commission.
(c) Availability.--On completion of the evaluation under subsection
(a), the Commission shall make the evaluation available to the Congress
and the public.
SEC. 10. TERMINATION.
The Commission shall terminate on June 1, 2020.
<all>
Introduced in House
Introduced in House
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line